803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer

• Philip D Greenberg,
• Valentin Voillet,
• Raphael Gottardo,
• Kristin G Anderson,
• Breanna M Bates,
• Madison G Burnett,
• Susan L Ruskin,
• Yapeng Su,
• Magdalia L Suarez Gutierrez

Affiliations

Philip D Greenberg

5University of Washington School of Medicine, Seattle, WA, USA

Valentin Voillet

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Raphael Gottardo

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Kristin G Anderson

2 University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia, USA

Breanna M Bates

Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Madison G Burnett

Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Susan L Ruskin

Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Yapeng Su

3Fred Hutchinson Cancer Center, Seattle, WA, USA

Magdalia L Suarez Gutierrez

3Fred Hutchinson Cancer Center, Seattle, WA, USA